- Through its partnership with Enoura Medical, ScreenPro has been approved by the National Health Services (NHS) to bid on NHS contracts
- The value of the NHS tender for the city of London alone is over 900 million GBP (equivalent to C$1.574 billion)
- Compel Capital, doing business as ScreenPro Security, provides fast and secure coronavirus screening
- Compel Capital (SCRN) opened trading at C$0.12 per share
ScreenPro Security (SCRN) has been approved to bid on NHS contracts.
The NHS of London is the medical agency for the City of London. To become a qualified supplier, the supplier and its product offering are stringently reviewed and approved by the National Health Service (NHS) prior to bidding.
Enoura Medical has been working with ScreenPro for the last five months positioning the company to provide solutions to the growing issues challenging London.
It is estimated that the overall value of the NHS tender for the city of London alone is over 900 million GBP (equivalent to C$1.574 billion). This illustrates the challenges faced by the NHS as it prepares to screen its citizens for all variants of the virus for the next two years.
John McMullen, ScreenPro CEO, stated, “This is a global pandemic and to be part of this opportunity with our partner, Enoura Medical, is one more channel to develop ScreenPro’s international profile and gain further revenue.
Being approved to bid on opportunities such as these tenders is a testament to the effectiveness and quality of solutions we provide. Our goal is to be at the forefront of coronavirus solutions to successfully and safely reopen society.”
Compel Capital, doing business as ScreenPro Security, is dedicated to the health and safety of the private workforce by providing fast, and secure coronavirus screening to detect the coronavirus and the new variants.
Compel Capital (SCRN) opened trading at C$0.12 per share.
